Istvan Petak: Pleasure to give a talk at the Drug Development Course 2024
Istvan Petak shared on LinkedIn:
“Hello, amazing Switzerland, beautiful Bellinzona. It was a pleasure to give a talk at the Drug Development Course 2024. I met outstanding clinical drug and biomarker development experts and pioneers of precision oncology. Translation of our understanding of tumor biology into clinical care becomes increasingly exciting. Thank you for inviting me to discuss how computational tools and artificial intelligence can help us overcome the dimensionality problem of the explosion of biological variables we can analyze and the treatment options we must choose from. Thank you for your exciting presentations, deep discussions, and friendship: Christophe Le Tourneau, France; Irene Brana, Spain; Anastasios Stathis, Prof MD, Switzerland; luca mazzarella, Italy and all the other faculty. I also thank the organizers and their institutions: IOSI Oncology Institute of Southern Switzerland – EOC) in collaboration with Institut Curie – Department of Drug Development and Innovation (D3i).”
Source: Istvan Petak/LinkedIn
.
Dr. Istvan Petak specialises in precision oncology and molecular pharmacology of targeted therapies. He is the founder and CEO of Genomate Health, Inc. Cambridge, MA, founder and board director of Oncompass Medicine, Budapest, HU, and adjunct professor at the Department of Pharmaceutical Sciences at the University of Illinois at Chicago (UIC).
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023